My Companies
Notification
Account
Log Out
Login
Management guided FY27 consolidated revenue of at least ₹1,550 crore and PAT of at least ₹178 crore (11.4% margin), with FY28 commercialisation of sickle-cell testing and medical devices. It proposed an energy demerger, affordable CAR-T centres, UK/Swiss subsidiaries, two oncology hospitals and 50 dialysis centres by March 2027.
Lord's Mark Receives India's First Biomescan SaMD Manufacturing Licence
Lord's Mark Industries Approves In-Principle MPS Plan With OFS And Rights Issue
Lords Mark Industries Commissions Vasai IVD Facility Two Months Early